BR112021026463A2 - Métodos para identificar um indivíduo a ser tratado por tempo de sono atrasado, para identificar um indivíduo em que o tempo de sono ou fase de sono pode ser atrasada, para identificar um indivíduo a ser tratado para um período circadiano alongado (tau), para identificar um indivíduo como alguém passível de alteração de um período circadiano (tau), e, para identificar um paciente a ser tratado para uma fase de sono atrasado devido ao tratamento com um inibidor de canal de nucleotídeo cíclico ativado por hiperpolarização (hcn) - Google Patents
Métodos para identificar um indivíduo a ser tratado por tempo de sono atrasado, para identificar um indivíduo em que o tempo de sono ou fase de sono pode ser atrasada, para identificar um indivíduo a ser tratado para um período circadiano alongado (tau), para identificar um indivíduo como alguém passível de alteração de um período circadiano (tau), e, para identificar um paciente a ser tratado para uma fase de sono atrasado devido ao tratamento com um inibidor de canal de nucleotídeo cíclico ativado por hiperpolarização (hcn)Info
- Publication number
- BR112021026463A2 BR112021026463A2 BR112021026463A BR112021026463A BR112021026463A2 BR 112021026463 A2 BR112021026463 A2 BR 112021026463A2 BR 112021026463 A BR112021026463 A BR 112021026463A BR 112021026463 A BR112021026463 A BR 112021026463A BR 112021026463 A2 BR112021026463 A2 BR 112021026463A2
- Authority
- BR
- Brazil
- Prior art keywords
- identify
- individual
- treated
- delayed
- tau
- Prior art date
Links
- 230000004622 sleep time Effects 0.000 title abstract 6
- 230000003111 delayed effect Effects 0.000 title abstract 5
- 230000002060 circadian Effects 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 206010012209 Delayed sleep phase Diseases 0.000 title abstract 2
- 230000004075 alteration Effects 0.000 title abstract 2
- 125000004122 cyclic group Chemical group 0.000 title abstract 2
- 230000002102 hyperpolarization Effects 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 208000017164 Chronobiology disease Diseases 0.000 abstract 3
- 239000012472 biological sample Substances 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- PTOIAAWZLUQTIO-GXFFZTMASA-N tasimelteon Chemical compound CCC(=O)NC[C@@H]1C[C@H]1C1=CC=CC2=C1CCO2 PTOIAAWZLUQTIO-GXFFZTMASA-N 0.000 abstract 1
- 229960000660 tasimelteon Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Anesthesiology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
métodos para identificar um indivíduo a ser tratado por tempo de sono atrasado, para identificar um indivíduo em que o tempo de sono ou fase de sono pode ser atrasada, para identificar um indivíduo a ser tratado para um período circadiano alongado (tau), para identificar um indivíduo como alguém passível de alteração de um período circadiano (tau), e, para identificar um paciente a ser tratado para uma fase de sono atrasado devido ao tratamento com um inibidor de canal de nucleotídeo cíclico ativado por hiperpolarização (hcn). a invenção se refere geralmente a transtornos do ritmo circadiano e, mais particularmente, ao tratamento ou prevenção de transtornos do ritmo circadiano com base no genótipo hcn1 de um indivíduo. um aspecto da invenção provê um método para tratar um indivíduo por tempo de sono atrasado compreendendo: determinar ou ter determinado a partir de uma amostra biológica do indivíduo que o indivíduo tem um genótipo gg no locus de polimorfismo de nucleotídeo único (snp) rs12188518; e administrar ao indivíduo uma vez por dia, antes de uma hora de dormir alvo, uma dose de tasimelteom eficaz para adiantar o tempo de sono do indivíduo. outros genótipos relacionados a transtornos do ritmo circadiano são cc em rs11248864 e aa em rs72762058.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962868881P | 2019-06-29 | 2019-06-29 | |
| PCT/US2020/040081 WO2021003086A1 (en) | 2019-06-29 | 2020-06-29 | Tasimelteon use in treating sleep aberrations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021026463A2 true BR112021026463A2 (pt) | 2022-02-08 |
Family
ID=71662374
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021026463A BR112021026463A2 (pt) | 2019-06-29 | 2020-06-29 | Métodos para identificar um indivíduo a ser tratado por tempo de sono atrasado, para identificar um indivíduo em que o tempo de sono ou fase de sono pode ser atrasada, para identificar um indivíduo a ser tratado para um período circadiano alongado (tau), para identificar um indivíduo como alguém passível de alteração de um período circadiano (tau), e, para identificar um paciente a ser tratado para uma fase de sono atrasado devido ao tratamento com um inibidor de canal de nucleotídeo cíclico ativado por hiperpolarização (hcn) |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220347150A1 (pt) |
| EP (1) | EP3989964A1 (pt) |
| JP (1) | JP7433345B2 (pt) |
| KR (1) | KR20220027977A (pt) |
| CN (1) | CN114641284A (pt) |
| AU (1) | AU2020299168B2 (pt) |
| BR (1) | BR112021026463A2 (pt) |
| CA (1) | CA3145247A1 (pt) |
| MX (1) | MX2021016059A (pt) |
| WO (1) | WO2021003086A1 (pt) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA9711051B (en) | 1996-12-10 | 1999-06-09 | Bristol Myers Squibb Co | Benzodioxole benzofuran dihydrobenzofuran and benzodioxane melatonergic agents |
| US20090105333A1 (en) | 2006-05-22 | 2009-04-23 | Gunther Birznieks | Melatonin agonist treatment |
| EP1925305A1 (en) * | 2006-10-23 | 2008-05-28 | N.V. Organon | Ih channel inhibitors for the promotion of wakefulness |
| KR20180100450A (ko) * | 2012-01-26 | 2018-09-10 | 반다 파마슈티칼즈, 인코퍼레이티드. | 일주기 리듬 장애의 치료 |
| MX2015007909A (es) * | 2012-12-18 | 2016-04-25 | Vanda Pharmaceuticals Inc | Tratamiento de trastornos del ritmo circadiano. |
| WO2016176333A1 (en) * | 2015-04-27 | 2016-11-03 | Reflex Medical, Inc. | Systems and mehtods for sympathetic cardiopulmonary neuromodulation |
-
2020
- 2020-06-29 US US17/621,447 patent/US20220347150A1/en active Pending
- 2020-06-29 CN CN202080060987.XA patent/CN114641284A/zh active Pending
- 2020-06-29 EP EP20742604.0A patent/EP3989964A1/en active Pending
- 2020-06-29 JP JP2021573304A patent/JP7433345B2/ja active Active
- 2020-06-29 MX MX2021016059A patent/MX2021016059A/es unknown
- 2020-06-29 KR KR1020227002080A patent/KR20220027977A/ko unknown
- 2020-06-29 BR BR112021026463A patent/BR112021026463A2/pt unknown
- 2020-06-29 CA CA3145247A patent/CA3145247A1/en active Pending
- 2020-06-29 WO PCT/US2020/040081 patent/WO2021003086A1/en unknown
- 2020-06-29 AU AU2020299168A patent/AU2020299168B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3989964A1 (en) | 2022-05-04 |
| WO2021003086A1 (en) | 2021-01-07 |
| JP2022538762A (ja) | 2022-09-06 |
| CN114641284A (zh) | 2022-06-17 |
| AU2020299168B2 (en) | 2024-05-09 |
| AU2020299168A1 (en) | 2022-01-27 |
| US20220347150A1 (en) | 2022-11-03 |
| JP7433345B2 (ja) | 2024-02-19 |
| MX2021016059A (es) | 2022-02-03 |
| CA3145247A1 (en) | 2021-01-07 |
| KR20220027977A (ko) | 2022-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Uno et al. | Glutamate hypothesis in schizophrenia | |
| Brook et al. | Skeletal muscle homeostasis and plasticity in youth and ageing: impact of nutrition and exercise | |
| Chang et al. | Medial prefrontal cortex activation facilitates re-extinction of fear in rats | |
| Cryan et al. | Withdrawal from chronic amphetamine induces depressive-like behavioral effects in rodents | |
| Nunes et al. | Disuse-induced skeletal muscle atrophy in disease and nondisease states in humans: mechanisms, prevention, and recovery strategies | |
| EA201100621A1 (ru) | Лечение диабета у пациентов, у которых наблюдается недостаточный гликемический контроль несмотря на лечение пероральным или непероральным противодиабетическим лекарственным средством | |
| EA200900940A1 (ru) | Фармацевтическая композиция, содержащая пиразол-о-глюкозидное производное | |
| DK1970059T3 (da) | Lægemiddel med calciumdobesilat til behandling og profylakse af senelidelser | |
| NO20053678L (no) | Kombinasjonsterapi for behandling av immuninflammatoriske forstyrrelser | |
| BRPI0608039A2 (pt) | células cancerìgenas sensìveis aos inibidores da histona deacetilase | |
| CY1110171T1 (el) | Ιατρικη χρηση αναστολεων γλουταμινικων και γλουταμικων κυκλασων για θεραπεια της ασθενειας του alzheimer και του συνδρομου down | |
| CO6640335A2 (es) | Tratamiento terapéutico para síndrome metabólico, diabetes de tipo 2, obesidad o prediabetes | |
| JP2020521794A5 (pt) | ||
| Ju et al. | The combination of long-term ketamine and extinction training contributes to fear erasure by Bdnf methylation | |
| EA202290024A1 (ru) | Способы лечения болезни фабри у пациентов с почечной недостаточностью | |
| Hurvitz et al. | Improving the effectiveness of anti-aging modalities by using the constrained disorder principle-based management algorithms | |
| CY1118486T1 (el) | Λαπατινιμπη για τη θεραπεια του καρκινου | |
| NO20076405L (no) | Anvendelse av 24-nor-UDCA | |
| Amano et al. | Opposite associations between the rs3845446 single-nucleotide polymorphism of the CACNA1E gene and postoperative pain-related phenotypes in gastrointestinal surgery versus previously reported orthognathic surgery | |
| BR112021026463A2 (pt) | Métodos para identificar um indivíduo a ser tratado por tempo de sono atrasado, para identificar um indivíduo em que o tempo de sono ou fase de sono pode ser atrasada, para identificar um indivíduo a ser tratado para um período circadiano alongado (tau), para identificar um indivíduo como alguém passível de alteração de um período circadiano (tau), e, para identificar um paciente a ser tratado para uma fase de sono atrasado devido ao tratamento com um inibidor de canal de nucleotídeo cíclico ativado por hiperpolarização (hcn) | |
| Balistreri et al. | Is it the time of seno-therapeutics application in cardiovascular pathological conditions related to ageing? | |
| IL175358A0 (en) | 1,4-dihydropyridine compounds, pharmaceutical compositions, and methods for the treatment of cardiovascular disease | |
| NO20054096L (no) | Inhibitor for perioperativ blodsukkerforhoyelse | |
| ATE546548T1 (de) | Verfahren zur prognose des nutzens einer antioxidationshemmenden therapie zur vorbeugung von herz-kreislauf-erkrankungen bei hyperglykämischen patienten | |
| Patel et al. | Epigenetics of Altered Circadian and Sleep Cycle Induced Effects on Aging and Longevity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |